Literature DB >> 28805598

Screening frequency and histologic type influence the efficacy of cervical cancer screening: A nationwide cohort study.

Ying-Cheng Chiang1, Yun-Yuan Chen2, Shu-Feng Hsieh1, Chun-Ju Chiang3, San-Lin You4, Wen-Fang Cheng5, Mei-Shu Lai6, Chi-An Chen1.   

Abstract

OBJECTIVE: To evaluate the influence of age, screening interval, and histologic type on the effect of Pap smears in cervical cancer screening.
MATERIALS AND METHODS: Data were retrieved from the Taiwan National Cancer Registry and Cervical Cancer Screening Registration System for the period from 2002 to 2010. Age, Pap smear interval, FIGO stage, and histology were further analyzed.
RESULTS: A total of 12,294 women with cervical cancer were enrolled, including 10,040 with squamous cell carcinoma (SCC), 1720 with adenocarcinoma (ADC), 401 with adenosquamous carcinoma (ASC), and 133 with small cell neuroendocrine carcinoma (SMC). Women who had a Pap smear at an interval of <3 years had a significantly higher proportion of stage I disease than women who had never undergone cervical cancer screening (p < 0.0001). Greater than 40% of women with SCCs in each age group had never had a Pap smear; however, women with ADCs were predominantly in the younger age and greater than 40% of women with ADCs had Pap smear at intervals < 3 years.
CONCLUSIONS: Pap smear is more effective in screening for cervical SCCs compared to cervical ADCs. Improving adherence to screening recommendations is important for the prevention of cervical SCC, especially in elderly women.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Adenocarcinoma; Cervical cancer; Pap smear; Squamous cell carcinoma

Mesh:

Year:  2017        PMID: 28805598     DOI: 10.1016/j.tjog.2017.01.010

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  7 in total

1.  Hyperphosphorylation of HDAC2 promotes drug resistance in a novel dual drug resistant mouse melanoma cell line model: an in vitro study.

Authors:  Bhuvanesh Sukhlal Kalal; Prashant Kumar Modi; Mohd Altaf Najar; Santosh Kumar Behera; Dinesh Upadhya; Thottethodi Subrahmanya Keshava Prasad; Vinitha Ramanath Pai
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

2.  Prevalence Oncogenic Human Papillomavirus in Cervical Cancer Patients in Riau Province Indonesia.

Authors:  Maya Savira; Donel Suhaimi; Andani Eka Putra; Yusrawati Yusrawati; Nur Indrawati Lipoeto
Journal:  Rep Biochem Mol Biol       Date:  2022-01

3.  Cancer Incidence Characteristic Evolution Based on the National Cancer Registry in Taiwan.

Authors:  Yu-Ching Huang; Yu-Hung Chen
Journal:  J Oncol       Date:  2020-07-22       Impact factor: 4.375

4.  Characterization of High-Risk HPV/EBV Co-Presence in Pre-Malignant Cervical Lesions and Squamous Cell Carcinomas.

Authors:  Rancés Blanco; Diego Carrillo-Beltrán; Juan P Muñoz; Julio C Osorio; Julio C Tapia; Verónica A Burzio; Iván Gallegos; Gloria M Calaf; Paola Chabay; Francisco Aguayo
Journal:  Microorganisms       Date:  2022-04-24

5.  Radical Hysterectomy After Neoadjuvant Chemotherapy for Locally Bulky-Size Cervical Cancer: A Retrospective Comparative Analysis between the Robotic and Abdominal Approaches.

Authors:  Chia-Hao Liu; Yu-Chieh Lee; Jeff Chien-Fu Lin; I-San Chan; Na-Rong Lee; Wen-Hsun Chang; Wei-Min Liu; Peng-Hui Wang
Journal:  Int J Environ Res Public Health       Date:  2019-10-11       Impact factor: 3.390

Review 6.  Splicing Genomics Events in Cervical Cancer: Insights for Phenotypic Stratification and Biomarker Potency.

Authors:  Flavia Zita Francies; Sheynaz Bassa; Aristotelis Chatziioannou; Andreas Martin Kaufmann; Zodwa Dlamini
Journal:  Genes (Basel)       Date:  2021-01-20       Impact factor: 4.096

7.  Impact of prior underinsurance on cervical cancer screening among Davidson County, Tennessee, women diagnosed with invasive cervical cancer, 2008-2018.

Authors:  Emmanuel N S Sackey; Manideepthi Pemmaraju; Marie R Griffin; Jessica L Castilho
Journal:  BMC Womens Health       Date:  2022-03-12       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.